OncoImmune

News

Merck & Co is to buy US biotech OncoImmune for at least $425m, adding a potential new therapy for COVID-19 to its pipeline.

News

Sanofi's CEO says adding to the group's pipeline through M&A and licensing will be "critical" as it prepares for generic competition to Dupixent.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.